Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Sensory Modulation in Children With Epilepsy

NCT06818344 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2025-03-01
Last updated
2025-02-12

Condition(s) studied

EpilepsySensory Modulation Disorder

Study summary

Epilepsy is a neurological condition that can impact cognitive, motor, and behavioral skills, often leading to sensory modulation disorders (SMDs) in children. These disorders impair sensory processing, affecting daily functioning and quality of life. This study aims to explore the sensory profiles of children with epilepsy and identify sensory modulation disorders.

The study will include 34 participants: 17 children with epilepsy and 17 healthy controls, aged 3-10 years. Inclusion criteria include at least one seizure in the past year, a diagnosis of epilepsy, and voluntary participation. Children with comorbid conditions such as cerebral palsy, autism, genetic disorders, or other neurological conditions will be excluded.

Data on demographics and epilepsy-related characteristics will be gathered from families. Sensory modulation will be assessed using the Sensory Profile, a 125-item Likert-type questionnaire completed by parents. It evaluates sensory processing across three categories: sensory processing, sensory modulation, and behavioral-emotional responses. Results will classify children as "Typical Performance," "Probable Difference," or "Definite Difference." Data will be analyzed using IBM SPSS 26.0 and R Software. The Shapiro-Wilk test will assess normality, followed by an Independent Samples t-test or Mann-Whitney U Test depending on data distribution. The Chi-Square test will be used for categorical variables.

This study aims to identify the prevalence and types of sensory modulation disorders in children with epilepsy. While previous studies suggest sensory processing issues in children with epilepsy, they often involve small samples. By using a larger sample, this research will provide stronger insights into the sensory profiles of children with epilepsy. The findings may contribute to earlier diagnosis and intervention strategies.

Future research should involve larger samples and longitudinal designs to investigate long-term effects and therapeutic approaches for sensory modulation disorders, ultimately improving the quality of life for children with epilepsy.

Eligibility

Sex
ALL
Min age
3 Years
Max age
10 Years
Healthy volunteers
Accepted
Inclusion Criteria: Having had a seizure in the year prior to data collection Clinical diagnosis of epilepsy Aged between 3 and 10 years Willing to participate in the study Exclusion Criteria: Diagnosis of cerebral palsy Diagnosis of hydrocephalus Diagnosis of autism spectrum disorder Diagnosis of pervasive developmental disorder Diagnosis of learning disabilities Diagnosis of dyslexia Diagnosis of genetic disorders Diagnosis of metabolic disorders Diagnosis of neuromuscular diseases

Primary outcome measure(s)

  • Sensory Profile — 1 year
    The Sensory Profile, developed by Winnie Dunn, is a 125-item Likert-type questionnaire used to assess how children aged 3-10 process sensory information from their bodies and environment. It is divided into three main sections: Sensory Processing, Modulation, and Behavioral and Emotional Responses. Sensory Processing includes subcategories such as auditory, visual, vestibular, tactile, multisensory, and oral processing. Modulation evaluates sensory processing related to endurance, movement, and body position, as well as the regulation of sensory inputs affecting emotional responses. Behavioral and Emotional Responses assess emotional, social responses, and behavioral consequences. Each section is scored based on frequency, and children are classified as having "typical performance," "probable difference," or "definite difference," based on the results. The test is widely used to evaluate sensory processing disorders in children.

Trial sites (1)

FacilityCityRegionStatus
Izzet Baysal University Bolu Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06818344 on ClinicalTrials.gov ↗ ← All trials in Turkey